Home >> Current Enzyme Inhibition, Volume 4, Number 3

The NPC1L1 Inhibitor Ezetimibe in the Treatment of the Dyslipidemia in Patients Affected by the Metabolic Syndrome: Evidences and Perspectives

Authors: Anfossi, Giovanni; Frascaroli, Chiara; Bonomo, Katia; Chirio, Massimo; Giordanino, Chiara; Trovati, Mariella

Source: Current Enzyme Inhibition, Volume 4, Number 3, October 2008 , pp. 109-120(12)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

OR

Price: $62.88 plus tax (Refund Policy)

Abstract:

Ezetimibe is the first lipid-lowering drug which selectively inhibits the intestinal uptake of dietary and biliary cholesterol by binding to the cholesterol transporter protein Niemann-Pick C1 Like 1 (NPC1L1). This drug is an effective new tool for cholesterol lowering and allows to better investigate the mechanisms involved in cholesterol absorption by small intestine.

Ezetimibe is rapidly absorbed after oral administration and extensively metabolized (>80%) to the pharmacologically active ezetimibe-glucuronide compound; furthermore, it shows a favourable drug-drug interaction profile due to the absence of clinically relevant interactions with a variety of drugs commonly used in patients with hypercholesterolemia (in particular, statins, fibrates and nicotinic acid). In primary hypercholesterolemia, ezetimibe alone reduces low density lipoprotein (LDL) cholesterol by about 18% and induces an additional 25% reduction when added to on-going statins. The combination therapy of ezetimibe with statins or fibrates is effective and safe also in patients affected by the Metabolic Syndrome, which is characterized by complex lipid alterations, including increased triglyceride levels, low high density lipoprotein (HDL) cholesterol concentrations, preponderance of small dense LDL particles and post-prandial hyperlipidemia.

In this review, we considered the main studies evaluating the rationale and the efficacy of therapy with ezetimibe alone or in combination with other lipid-lowering drugs, in order to provide clinical indications.

More about this publication?
  • Current Enzyme Inhibition aims to publish all the latest and outstanding developments in enzyme inhibition studies with regards to the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of enzymes that can be exploited for drug development. Current Enzyme Inhibition is an essential journal for every pharmaceutical and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.
Related content
Marked list

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
^ Back to top
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page